This suggests that the anti-CD96 and anti-PD-1 antibodies induced considerably different amounts of ADAs, indicating that the mAbs triggered very different extents of immunogenicity in the mouse colon cancer model. The gene discussed is CD96; the disease is colonic neoplasm.